NCT05610787

EXCOR Active Driving System for the EXCOR Pediatric VAD IDE Study

Enrolling by Invitation
NAUp to 21InterventionalTreatment
Berlin Heart, Inc
~40 participants
Updated 2026-03-04 on ClinicalTrials.gov
What's tested:EXCOR Active Driving System for Pediatric VAD

At a glance

Recruiting sites
0 of 15 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Rate of Device Malfunction adverse events
Measured over Up to 90 days
+2 more outcomes measured
Heart Failure
Transplant; Failure, Heart
Congenital Heart Disease
15 sites across 14 states
California2
Colorado1
District of Columbia1
Florida1
Illinois1
Massachusetts1
Missouri1
New York1

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patient meets all indications as specified in the current version of the Instructions for Use (IFU) of the EXCOR® Pediatric VAD system as shown below:

Exclusion

Patient and/or legal representative has not given written consent to participate in the study (non-consent).
Females of childbearing age who are not on contraceptives or surgically sterile or pregnant.
  • Rate of Device Malfunction adverse eventsUp to 90 days

    A Device Malfunction per protocol definition, and adjudicated by the Clinical Events Committee.

  • Patient OutcomeUp to 90 days

    Patient outcomes will be summarized as the proportion of subjects experiencing each outcome and the overall successful outcome. Successful outcome is defined as: * survival to recovery/successful weaning -or- * survival to explantation not attributed to device malfunction -or- * survival on EXCOR® Pediatric at 90 days post-implant Patients who are removed from support followed by death or for escalation to other therapy (such as another VAD or ECMO) due to major device malfunction attributed to the Active Driving System will be considered failures.

  • Serious Adverse EventsUp to 90 days

    Serious Adverse Event rates will be calculated as the rate per 100 patient-months for each individual event as defined in protocol.